Nasus Pharma initiated with an Outperform at Citizens

Citizens initiated coverage of Nasus Pharma (NSRX) with an Outperform rating and $19 price target The firm says the company uses its Nasax platform to develop dry powder-based intranasal therapies for emergency medical conditions. The opportunity for needle-free alternatives to epinephrine autoinjectors like the EpiPen is “large and compelling,” and the introduction of multiple needle-free alternatives will drive a majority market share in coming years, the analyst tells investors in a research note. Citizens believes Nasus Pharma’s NS002 has the potential to be the “best-in-class” nasal spray epinephrine.